Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with more than one million new diagnoses annually.

Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors ...

Results were announced from a trial evaluating durvalumab with FLOT chemo as perioperative treatment for resectable early stage gastric/GEJ cancers.

FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumorsCabozantinib ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with ...

Medically reviewed by Marla Anderson, MD Stomach cancer—or gastric cancer—occurs when cells in the lining of the stomach wall ...

For the first time, scientists have systematically analyzed somatic mutations in stomach lining tissue to unpick mutational processes, some of which can lead to cancer. The team also uncovered hints ...

If you regularly develop gas, bloating, diarrhea, vomiting, or upset stomach after eating dairy products, consider switching to a lactose-free option or a plant-based dairy alternative, such as: ...

This significant leap is attributed to rising incidences of carcinoid tumors, especially in the lungs and gastrointestinal tract, matched with an increase in the development and utilization of ...